New study digs into how mepolizumab changes nose bacteria and genes in asthma patients
NCT ID NCT06069310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and gene activity. The goal is to find patterns that predict who responds best to treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pulmonary Dept First ICU Evangelismos Hospital
Athens, 10676, Greece
-
Pulmonary Dept First ICU, Evagelismos Hospital
Athens, Attica, 10676, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug that calms inflammation ease chronic sinusitis?
- Can a new drug shrink nasal polyps and restore smell?
- Beyond breathing: could an asthma drug lift emotional burdens for patients and partners?
- Smart inhalers track Fasenra's asthma control over full dosing cycle
- Greek sinusitis study aims to personalize treatment by analyzing inflammation
- CT scan could predict asthma drug success, saving months of trial and error